Streetbeat News

Price Targets

NVDA

Citigroup analyst Atif Malik maintains a Buy rating on NVIDIA and raises the price target from $305 to $363.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:22 am

ACR

Raymond James analyst Stephen Laws maintains an Outperform rating on ACRES Commercial Realty (NYSE:ACR) but lowers the price target from $13.5 to $12.5.

Portfolio Pulse from richadhand@benzinga.com

May 24, 2023 | 11:21 am

INTU

Morgan Stanley analyst Keith Weiss maintains an Overweight rating on Intuit (NASDAQ:INTU) and raises the price target from $520 to $525.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:21 am

PANW

Wells Fargo analyst Andrew Nowinski maintains an Overweight rating on Palo Alto Networks (NASDAQ:PANW) and raises the price target from $250 to $265.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:21 am

PANW

Raymond James analyst Adam Tindle maintains an Outperform rating on Palo Alto Networks (NASDAQ:PANW) and raises the price target from $215 to $230.

Portfolio Pulse from richadhand@benzinga.com

May 24, 2023 | 11:20 am

A

Wells Fargo analyst Dan Leonard maintains an Overweight rating on Agilent Technologies (NYSE:A) but lowers the price target from $170 to $160.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:19 am

ZURA

Raymond James analyst Steven Seedhouse initiates coverage on Zura Bio (NASDAQ:ZURA) with a Strong Buy rating and announces a price target of $20.

Portfolio Pulse from richadhand@benzinga.com

May 24, 2023 | 11:19 am

DAVA

Susquehanna analyst James Friedman maintains a Positive rating on Endava (NYSE:DAVA) but lowers the price target from $112 to $104.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:18 am

WVE

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on WAVE Life Sciences (NASDAQ:WVE) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

May 24, 2023 | 11:16 am

TRDA

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Entrada Therapeutics (NASDAQ:TRDA) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

May 24, 2023 | 11:15 am